Language: Français

Thrombotic Thrombocytopenic Purpura

 Thrombotic Thrombocytopenic Purpura (9891-08) Discuss the diagnosis, testing, treatment and outcomes of patients with Thrombotic Thrombocytopenic Purpura (TTP), while adding some details from an historical perspective. Version Date: October 2008

Code 9891-08
Level Advanced

Member Price


Non-Member Price



Additional Details

PEP hours: 6
CPS credits: 0.4
Level: Advanced
Course Type: Express
Start Date: Upon registration
Completion: Up to 52 weeks
Delivery: PDF via email
Learning Outcomes:
  • Describe briefly the history of TTP prior to its link to the von Willebrand factor
  • Explain conceptually the clinical difference between a decreased concentration compared to a functionally impaired vWF
  • Describe the two primary functions of vWF
  • Explain, in general terms, the functional difference between the sizes of circulating vWF multimers
  • Outline the effects of DDAVP on the circulating vWF
  • List the five features that are considered the hallmark of TTP
  • Describe the key clinical reports that outline the key observations linking TTP to the vWF
  • Briefly describe the epidemiology of TTP
  • List the organ which is thought to be the main production site for ADAMTS-13
  • Describe the exact cleavage site for ADAMTS-13 in a vWf multimer
  • Outline the genetics of TTP
  • Explain the nature of ADAMTS 13 metalloproteinase
  • Describe in more detail the clinical findings in TTP
  • Discuss the possible mechanisms by which inhibitory antibodies can cause TTP in an affected individual
  • Describe the differences between TTP and HUS
  • Outline the laboratory approach to confirming the diagnosis of TTP
  • Describe the theory of the various approaches of treatment of TTP
  • Discuss the relative advantages and disadvantages of the protocols for the treatment of TTP
Author/Instructor: Linda Stang, MLT
Version Date: October 2008